Compare Stocks: ATXI, RDHL, GLMD, and GRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.26	$0.30	$0.15 ▼ $0.97	$849K	-0.2	5,619 shs	2,757 shs
GLMD Galmed Pharmaceuticals	$0.52 -0.2%	$0.56	$0.41 ▼ $1.65	$3.45M	0.74	243,327 shs	37,492 shs
GRI GRI Bio	$1.67	$1.77	$1.36 ▼ $80.36	$2.96M	-1.2	395,528 shs	105,236 shs
RDHL Redhill Biopharma	$0.58 -3.7%	$0.74	$0.58 ▼ $2.79	$3.51M	5	38,390 shs	8,259 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	+0.98%	+3.04%	-16.85%	-54.81%
GLMD Galmed Pharmaceuticals	0.00%	-13.27%	-4.38%	-10.42%	-63.75%
GRI GRI Bio	0.00%	+13.61%	+11.33%	-21.96%	-95.71%
RDHL Redhill Biopharma	0.00%	-4.46%	-18.01%	-38.08%	-57.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.26	$0.30	$0.15 ▼ $0.97	$849K	-0.2	5,619 shs	2,757 shs
GLMD Galmed Pharmaceuticals	$0.52 -0.2%	$0.56	$0.41 ▼ $1.65	$3.45M	0.74	243,327 shs	37,492 shs
GRI GRI Bio	$1.67	$1.77	$1.36 ▼ $80.36	$2.96M	-1.2	395,528 shs	105,236 shs
RDHL Redhill Biopharma	$0.58 -3.7%	$0.74	$0.58 ▼ $2.79	$3.51M	5	38,390 shs	8,259 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	+0.98%	+3.04%	-16.85%	-54.81%
GLMD Galmed Pharmaceuticals	0.00%	-13.27%	-4.38%	-10.42%	-63.75%
GRI GRI Bio	0.00%	+13.61%	+11.33%	-21.96%	-95.71%
RDHL Redhill Biopharma	0.00%	-4.46%	-18.01%	-38.08%	-57.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
GRI GRI Bio	2.00	Hold	$32.00	1,816.17% Upside
RDHL Redhill Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATXI, RDHL, GLMD, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	RDHL Redhill Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/1/2026	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $32.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$2.88 per share	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A
RDHL Redhill Biopharma	$290K	12.12	N/A	N/A	$0.83 per share	0.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$0.85	0.01	N/A	N/A	N/A	-471.57%	-296.50%	N/A
GLMD Galmed Pharmaceuticals	-$10.31M	-$0.91	N/A	N/A	N/A	N/A	-35.32%	-30.94%	8/17/2026 (Estimated)
GRI GRI Bio	-$11.96M	-$74.16	N/A	N/A	N/A	N/A	-156.24%	-116.90%	N/A
RDHL Redhill Biopharma	-$430K	$900.00	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2026 (Estimated)

Latest ATXI, RDHL, GLMD, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	H1 2026	RDHL Redhill Biopharma	-$435.00	N/A	N/A	N/A	$22.70 million	N/A
8/17/2026	N/A	GLMD Galmed Pharmaceuticals	-$0.39	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
GLMD Galmed Pharmaceuticals	N/A	7.71	7.71
GRI GRI Bio	N/A	14.20	14.21
RDHL Redhill Biopharma	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
GLMD Galmed Pharmaceuticals	76.14%
GRI GRI Bio	33.95%
RDHL Redhill Biopharma	7.20%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	8.60%
GLMD Galmed Pharmaceuticals	19.80%
GRI GRI Bio	8.73%
RDHL Redhill Biopharma	6.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.30 million	2.02 million	Not Optionable
GLMD Galmed Pharmaceuticals	20	6.60 million	5.29 million	Not Optionable
GRI GRI Bio	1	1.77 million	1.62 million	Not Optionable
RDHL Redhill Biopharma	210	6.08 million	5.67 million	No Data

ATXI, RDHL, GLMD, and GRI Headlines

Recent News About These Companies

Redhill Biopharma (RDHL) Expected to Post Quarterly Earnings on Thursday

August 13, 2026 | americanbankingnews.com

Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research

August 8, 2026 | intelligentinvestor.com.auI

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

July 28, 2026 | prnewswire.com

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

June 22, 2026 | prnewswire.com

RedHill Biopharma announces up to $19.4M private placement

June 18, 2026 | msn.com

RedHill Biopharma Announces Up To $19.4 Million Private Placement

June 18, 2026 | prnewswire.com

RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak

June 13, 2026 | theglobeandmail.com

RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

June 9, 2026 | finanznachrichten.de

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

June 9, 2026 | prnewswire.com

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

June 8, 2026 | prnewswire.com

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

June 2, 2026 | prnewswire.com

Bessor Announces Entering Option for the Redhill Property

May 26, 2026 | globenewswire.com

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

April 30, 2026 | prnewswire.com

RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

April 27, 2026 | finanznachrichten.de

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

April 27, 2026 | prnewswire.com

RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...

April 23, 2026 | finanznachrichten.de

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

April 22, 2026 | prnewswire.com

Joint U.S. Commercialization of RedHill's Talicia® Commences

February 25, 2026 | prnewswire.com

Redhill Biopharma stock soars on GLP-1 side effect treatment progress

January 5, 2026 | investing.com

RedHill Biopharma shares jump on progress toward treating GLP-1 side effects

January 5, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATXI, RDHL, GLMD, and GRI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.26 0.00 (0.00%)

As of 08/14/2026 02:04 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Galmed Pharmaceuticals NASDAQ:GLMD

$0.52 0.00 (-0.21%)

Closing price 08/14/2026 03:35 PM Eastern

Extended Trading

$0.49 -0.03 (-5.94%)

As of 08/14/2026 07:57 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GRI Bio NASDAQ:GRI

$1.67 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.70 +0.03 (+1.80%)

As of 08/14/2026 07:53 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Redhill Biopharma NASDAQ:RDHL

$0.58 -0.02 (-3.65%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$0.58 +0.00 (+0.52%)

As of 08/14/2026 07:55 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXI, RDHL, GLMD, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXI, RDHL, GLMD, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXI, RDHL, GLMD, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATXI, RDHL, GLMD, and GRI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

Redhill Biopharma NASDAQ:RDHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXI, RDHL, GLMD, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXI, RDHL, GLMD, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXI, RDHL, GLMD, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATXI, RDHL, GLMD, and GRI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

Redhill Biopharma NASDAQ:RDHL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools